Wikipedia -WSS

Wikipedia

author：hotspot 2025-10-01 00:46:44 - browse：93

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Covid silver lining: Unprecedented look at human immune system

WSS

Biden’s NIH nominee is languishing in Congress

U.K. decision on ALS drug has neurologists, advocates up in arms

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Scientific mystery highlights the blind spots in genomics databases

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Presidential fundraising highlights so far: Trump brings in more than DeSantis

hotspot

Wikipedia

focus

Cancer drug shortages should be causing more outrage

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Hollywood unions extend contract negotiations for actors

ACA's risk program benefits Blue Cross Blue Shield insurers

Drug repurposing or repositioning? The language matters

Overprescribed: High cost isn't America's only drug problem

In age of alternative facts, a scholarly course on calling out crap

Eisai exec who led development of Alzheimer’s drug to retire

After affirmative action ruling, medical educators look to 'holistic review'

First Opinion on colorectal cancer screening: letter and response

leisure time

Biden declares emergency in flood

Bird flu reported in person exposed to presumably infected cattle

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Eisai exec who led development of Alzheimer’s drug to retire

hotspot

explore

focus

leisure time